You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DPP4

Showing 1 - 25 of 693
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ive Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Active, not recruiting
  • Diabetes
  • Boston, Massachusetts
    Brigham and Women's Hospital
Mar 3, 2023

Time in Range Trial in Cairo (Dipeptidyl peptidase-4 inhibitors)

Completed
  • Time in Range
  • Dipeptidyl peptidase-4 inhibitors
  • Cairo, Egypt
    Nancy Elbarbary
Aug 26, 2023

Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,

Recruiting
  • Glucose Metabolism Disorders
  • +3 more
  • Empagliflozin 10 MG
  • Insulin+Metformin+DPP4 inhibitor (DPP4I)
  • Karachi, Pakistan
    SINA Shireen Jinnah colony
Nov 28, 2023

Diabete Type 2 Trial in El Sadat (Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG)

Completed
  • Diabete Type 2
  • Sitagliptin 50 mg
  • +3 more
  • El Sadat, Egypt
    University of Sadat City
Apr 27, 2022

Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,

Completed
  • Diabetes Mellitus, Type 2
  • One Or Multiple Sites, United Kingdom
    RTI health solutions
Aug 2, 2022

Dipeptidyl Peptidase-4 Link With Oral Cancer and Premalignant

Completed
  • Oral Premalignant Lesions as Leukoplakia and Lichen Planus
  • Oral Cancer
  • serum and unstimulated salivary samples
  • Fayoum, Egypt
    faculty of dentistry, Fayoum university
Oct 16, 2023

Genetics Disease, Type2 Diabetes, Heart Failure Trial in Philadelphia (Sitagliptin 100mg, Placebo Oral Tablet)

Recruiting
  • Genetics Disease
  • +2 more
  • Sitagliptin 100mg
  • Placebo Oral Tablet
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Dec 30, 2021

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
  • Type 2 Diabetes Mellitus
  • Cardiovascular Diseases
  • Oakland, California
  • +5 more
Oct 18, 2022

NAFLD Trial (sitagliptin and metformin, Sitagliptin, Metformin)

Completed
  • NAFLD
  • sitagliptin and metformin
  • +2 more
  • (no location specified)
Jul 28, 2022

Type 2 Diabetes, Hypertension Trial in Nashville (Placebo, Sitagliptin, Aprepitant)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Hypertension
  • Placebo
  • +3 more
  • Nashville, Tennessee
    Vanderbilt University
Feb 8, 2022

Harmonizing RCT-Duplicate Emulations In A Real World Replication

Completed
  • Type 2 Diabetes Mellitus
  • Gothenburg, Sweden
    Research Site
Oct 23, 2023

Based on Data From German Sick Funds That Looks at Costs of

Completed
  • Diabetes Mellitus, Type 2
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
Jan 18, 2022

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Diabetes, Stroke Trial in Chiayi City (Metformin plus Pioglitazone plus an SGLT2 inhibitor)

Recruiting
  • Diabetes Mellitus
  • Stroke
  • Metformin plus Pioglitazone plus an SGLT2 inhibitor
  • Chiayi City, Taiwan
    Chang Gung Memorial Hospital, Chiayi Branch
Jan 11, 2022

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

Metformin and DPP4 Inhibitors on Cognition and Cardiovascular

Recruiting
  • Type 2 Diabetes Mellitus
  • Cairo, Al Kasr Al Aini, Egypt
    National Institute of diabetes and endocrinology
Jun 19, 2022

DPP4 Inhibitor and Coronary Atherosclerosis in Patients

Completed
  • Diabetes Mellitus
  • Bucheon, Korea, Republic of
    Bucheon St. Mary's Hospital
Apr 26, 2021

Understand How Oral Semaglutide Works in People With Type 2

Enrolling by invitation
  • Diabetes Mellitus, Type 2
  • Bologna, Italy
  • +17 more
Feb 23, 2023

Replication of SEPRA Diabetes Trial in Healthcare Claims Data

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • New use of semaglutide injection
  • New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
  • Boston, Massachusetts
    Brigham and Women's Hospital
Oct 10, 2022

Healthy Volunteers Trial (gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), gemigliptin and dapagliflozin

Not yet recruiting
  • Healthy Volunteers
  • gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)
  • gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)
  • (no location specified)
Oct 24, 2021

Coronavirus Infection, Type 2 Diabetes Trial in Miami (Linagliptin, Insulin regimen)

Withdrawn
  • Coronavirus Infection
  • Type 2 Diabetes
  • Miami, Florida
    University of Miami
Jun 7, 2021

Type 2 Diabetes Trial in Dundee (Sulfonylurea, DPP4 Inhibitor)

Completed
  • Type 2 Diabetes
  • Dundee, United Kingdom
    Ninewells Hospital and Medical School
Mar 3, 2021

Healthy Trial in Durham (Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin)

Completed
Has Results
  • Healthy
  • Active Comparator: Sitagliptin
  • Placebo Comparator - No Sitagliptin
  • Durham, North Carolina
    Leslie Willis
Apr 6, 2021

Empa PASS on Urinary Tract Malignancies

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Helsinki, Finland
  • +2 more
Aug 8, 2022

Type II Diabetes in Subjects BMI 27 to 32 Trial in Singapore (Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical)

Completed
  • Type II Diabetes in Subjects BMI 27 to 32
  • Roux-en-Y Gastric Bypass (RYGB)
  • +4 more
  • Singapore, Singapore
    Khoo Teck Puat Hospital
Jun 22, 2022